KMT2A-ARHGEF12, a therapy related fusion with poor prognosis.
Fiche publication
Date publication
août 2021
Journal
Molecular biology reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GARNACHE-OTTOU Francine
Tous les auteurs :
Assaf N, Liévin R, Merabet F, Raggueneau V, Osman J, Kim R, Garnache F, D'Angiò M, Larghero P, Meyer C, Marschalek R, Rousselot P, Terré C
Lien Pubmed
Résumé
The detection of KMT2A gene rearrangements have an important impact on the prognosis and management of acute leukemias. These alterations most commonly involve reciprocal translocations at specific breakpoint regions within KMT2A. To date, more than 100 translocation partner genes of KMT2A have been identified, with different effects on risk stratification.
Mots clés
ARHGEF12, Acute lymphoid leukemia, Acute myeloid leukemia, KMT2A, Plasmacytoid dendritic cell
Référence
Mol Biol Rep. 2021 Aug 12;: